

# Amniotic membrane-based antimicrobial agent

**Field of use**  
Healthcare-Medical Science

**Current state  
of technology**  
Laboratory tested;  
preclinical

**Intellectual property**  
Patent pending,  
LU101112

**Developed by**  
University of Ljubljana,  
Medical Faculty

**Reference**  
821-19/2018

**Contact**

Knowledge Transfer Office,  
University of Ljubljana

Gabriela Droga Mazovec  
Phone: +386 1 2418 533  
E-mail: ipr@uni-lj.si



**Background**

During the years 2000 and 2015, the use of antibiotics worldwide increased for 65%. Epidemiological studies showed the correlation between the increasing use of antibiotics and the emergence and spreading of bacteria, resistant to antibiotics. The studies show there is a great need for discovery and development of novel antimicrobials.

**Description of the Invention**

The developed mammalian amniotic membrane homogenate can be used as an antimicrobial agent. The preparation of which runs through a well-determined procedure so that its antibacterial characteristics remain intact.

**Main Advantages**

Antimicrobial activity of amniotic membrane has been proven against several bacteria, namely *Escherichia coli*, *Staphylococcus aureus*, *Enterobacter sp.*, *Klebsiella pneumoniae*, *Staphylococcus saprophyticus* and others. The preparation procedure is simple and cost-effective and the homogenate presents a high efficacy rate.